Innate Pharma to Hold its Annual General Meeting of Shareholders on May 28, 2021
Innate Pharma to Hold its Annual General Meeting of Shareholders on
May 28, 2021
Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421;
Nasdaq: IPHA) (“Innate
” or the
”) will hold its Annual General Meeting of
”) at 11:00 a.m. CET on May 28,
2021. The Annual General Meeting will be broadcasted live.
The procedures for holding the AGM have been
adapted in accordance with French Ordinance No. 2020-321 of 25
March 2020 (as modified by French Ordinance n°2020-1497 of December
2, 2020) and French Decree No. 2020-418 of April 10, 2020 (as
modified by French Decree No. 2020-1614 of December 18, 2020),
extended by French Decree No. 2021-55 of March 9, 2021.
At the date of this publication, administrative
measures limiting or prohibiting travel or collective gatherings
for health reasons in France prevent the physical presence of its
members to the AGM.
In this exceptional context, the shareholders
are invited to vote before the AGM by correspondence or through a
The shareholders will be able to send questions
during the AGM. The connection details and the recording will be
available on the Company’s website (www.innate-pharma.com).
The Notice of Meeting of this AGM was published
on April 21, 2021 in the French legal bulletin. It includes the
agenda, the proposed resolutions as well as instructions to
participate and vote in this AGM.
All documentation regarding this AGM will be
published on the Company’s website.
Precision regarding the
Only shareholders having registered their shares
at least two business days prior to the date of the AGM, by
midnight Paris time, will be able to participate.
Shareholders holding “au porteur” (bearer)
shares will need to obtain an “attestation de participation”
(certificate of shareholding) from their brokers. This “attestation
de participation” must be attached to the voting or proxy form.
Written questions from shareholders must be
received the second business day prior to the AGM at the latest (by
e-mail to email@example.com).
Shareholders may obtain the legal documentation
in preparation of the AGM (as described in article R. 225-83 of the
French Code de Commerce) by sending a request by e-mail to
About Innate Pharma:
Innate Pharma S.A. is a global, clinical-stage
oncology-focused biotech company dedicated to improving treatment
and clinical outcomes for patients through therapeutic antibodies
that harness the immune system to fight cancer.
Innate Pharma’s broad pipeline of antibodies
includes several potentially first-in-class clinical and
preclinical candidates in cancers with high unmet medical need.
Innate has been a pioneer in the understanding
of natural killer cell biology and has expanded its expertise in
the tumor microenvironment and tumor-antigens, as well as antibody
engineering. This innovative approach has resulted in a diversified
proprietary portfolio and major alliances with leaders in the
biopharmaceutical industry including Bristol-Myers Squibb, Novo
Nordisk A/S, Sanofi, and a multi-products collaboration with
Headquartered in Marseille, France, with a US
office in Rockville, MD, Innate Pharma is listed on Euronext Paris
and Nasdaq in the US.
Learn more about Innate Pharma at
Information about Innate Pharma
code Ticker code
Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29
This press release contains certain
forward-looking statements, including those within the meaning of
the Private Securities Litigation Reform Act of 1995.The use of
certain words, including “believe,” “potential,” “expect” and
“will” and similar expressions, is intended to identify
forward-looking statements. Although the company believes its
expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those anticipated. These risks and uncertainties
include, among other things, the uncertainties inherent in research
and development, including related to safety, progression of and
results from its ongoing and planned clinical trials and
preclinical studies, review and approvals by regulatory authorities
of its product candidates, the Company’s commercialization efforts,
the Company’s continued ability to raise capital to fund its
development and the overall impact of the COVID-19 outbreak on the
global healthcare system as well as the Company’s business,
financial condition and results of operations. For an additional
discussion of risks and uncertainties which could cause the
company's actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque")
section of the Universal Registration Document filed with the
French Financial Markets Authority (“AMF”), which is available on
the AMF website http://www.amf-france.org or on Innate Pharma’s
website, and public filings and reports filed with the U.S.
Securities and Exchange Commission (“SEC”), including the Company’s
Annual Report on Form 20-F for the year ended December 31, 2019,
and subsequent filings and reports filed with the AMF or SEC, or
otherwise made public, by the Company.
This press release and the information contained
herein do not constitute an offer to sell or a solicitation of an
offer to buy or subscribe to shares in Innate Pharma in any
For additional information, please
Tel.: +33 (0)4 30 30 30 30 firstname.lastname@example.org
Media Innate Pharma Tracy Rossin
(Global/US) Tel.: +1 240 801 0076 Tracy.Rossin@innate-pharma.com
ATCG Press Marie Puvieux (France) Tel.: +33 (0)9
81 87 46 72 email@example.com